Temsirolimus failed to show efficacy for recurrent GBM in Phase II clinical trial.112 Sirolimus also had little efficacy for treatment of recurrent GBM patients even when combined with the EGFR tyrosine kinase inhibitor Erlotinib.113 Similarly, Everolimus did not convey a significant survival benefit when combined with temozolomide and radiotherapy in a phase II trial for newly diagnosed GBM patients.114 On the other hand, AZD2014 (Vistusertib), CC-223 (TORKi) and Palomid 529, which are dual mTORC1/mTORC2 inhibitors, have shown therapeutic promise. Here, EGFR is linked to glioblastoma.